New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
08:48 EDTFMIFoundation Medicine data to have positive effect on reimbursement, says Wedbush
After clinical data on gene fusion detection indicated that such detection led to clinical action in about 15% of patients, Wedbush thinks the 15% level will be more than enough for large payors to recognize the importance of deep tumor profiling in some patients. The firm thinks the recent increase in reimbursement rates for BRCA pricing is positive for long-term FoundationOne reimbursement. Wedbush keeps a $50 price target and Outperform rating on Foundation Medicine.
News For FMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
16:34 EDTFMIThird Rock Ventures reports 2.4% stake in Foundation Medicine
Subscribe for More Information
April 20, 2015
08:32 EDTFMIFoundation Medicine appoints Timothy Dec as interim CFO
OpGen announced the expansion of its executive management team with the appointments of former Foundation Medicine executive Kevin Krenitsky as president, and Timothy C. Dec as interim CFO. Dec has more than 20 years of public company financial leadership experience in technology and healthcare, and will be charged with ensuring a smooth transition for OpGen from private to public company status and with public company reporting responsibilities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use